RecruitingPhase 3NCT06275035

Evaluation of Memantine in the Preservation of Memory and Neurocognition Following CSI

Memantine to Preserve Memory and Neurocognition Following Craniospinal Irradiation- A Randomised Controlled Trial (MEMENTO)

Sponsor

Tata Memorial Centre

Enrollment

101 participants

Start Date

Feb 22, 2024

Study Type

INTERVENTIONAL

Conditions

Neurocognitive Dysfunction

Summary

The goal of this clinical trial is to evaluate the role of memantine in preservation of memory and neurocognition in patients undergoing craniospinal irradiation. Participants will be randomised into two arms and the interventional arm will receive memantine along with the standard treatment. Researchers will compare the neurocognitive tests of participants in both the arms to see if memantine leads to significant preservation of memory and cognition post radiation therapy.

Eligibility

Min Age: 5 YearsMax Age: 39 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Memantine Oral Tablet for people with neurocognitive dysfunction. The study is currently recruiting participants at 1 location. People eligible for this study include aged 5 Years to 39 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.